Previous 10 | Next 10 |
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal fourth quarter 2023 financial results on Thursday, April 27, 2023, after the market closes. In conjunction, the compan...
2023-04-04 17:08:18 ET Gainers: Roivant Sciences ( ROIV ) +5% . Leonardo DRS ( DRS ) +4% . Kura Sushi USA ( KRUS ) +4% . SomaLogic ( SLGC ) +4% . Accolade ( ACCD ) +4% . Losers: Verona Pharma ( VRNA ) -4...
2023-03-23 10:59:18 ET Shares of IT-led healthcare services company Accolade ( NASDAQ: ACCD ) added ~13% on Thursday to reach an 11-month high after Guggenheim upgraded it to Buy from Neutral, citing an improved profitability outlook. The analyst Sandy Draper said that...
Accolade Welcomes Lyra Health to Its Trusted Partner Ecosystem PR Newswire Accolade and Lyra will offer employers purpose-built integrations that help address barriers to behavioral health care SEATTLE , March 6, 2023 /PRNewswire/ -- Accolade, Inc. (Nasda...
SEATTLE, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced changes to its Board of Directors. The Company announced today that long-time executive Michael Hilton will step down from his operating role at the Company to join the Board of Directors, replacing Tom Neff,...
Blue Shield of California Launches Virtual Blue Benefit Plan Incorporating Primary, Mental Health, and Specialty Care PR Newswire The nonprofit health plan teams up with Accolade and TeleMed2U to connect members to virtual and in-person care through a new, virtual-first plan. ...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
Shares of Accolade (NASDAQ: ACCD) were up as much as 25% for the week early Friday, according to data provided by S&P Global Market Intelligence . The stock closed last week at $7.43 a share, and then rose to as high as $10.01 on Tuesday. It saw a 52-week low of $4.61 and a 52-wee...
Summary The US healthcare system is hard to navigate. ACCD's strong competitive advantage is its proprietary platform. 3Q23 demonstrated solid bookings and growth. Investment thesis I recommend going long Accolade ( ACCD ). The challenges faced by individuals navig...
Accolade ( NASDAQ: ACCD ) stock rose ~23% on Tuesday after FQ3 2023 revenue grew 9% Y/Y and the company provided outlook for fiscal '23 and '24. FQ3 revenue increased to $90.95M, compared to $83.45M in FQ3 fiscal 2022. GAAP EPS of -$0.56, compared to $0.31 in the...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...